
ASAM eLearning
Catalog Advanced Search
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Philadelphia, PA - Monday, October 21, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Monday, October 21, 2019 | 8:00 am - 12:30 pm
Pennsylvania Convention Center
1101 Arch St
Philadelphia, PA 19107Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Macungie, PA - Friday, November 1, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Friday, November 1, 2019 | 8:00 am - 12:30 pm
Bear Creek Mountain Resort 2052
101 Doe Mountain Ln
Macungie, PA 18062Please register with the PA Department of Health prior to the course here: https://www.surveymonkey.com/r/MAT_Summit_Registration
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Erie, PA - Tuesday, November 5, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Tuesday, November 5, 2019 | 8:00 am - 12:30 pm
Bayfront Convention Center
1 Sassafras Pier
Erie, PA 16507Please register with the PA Department of Health prior to the course here: https://www.surveymonkey.com/r/MAT_Summit_Registration
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Williamsport, PA - Thursday, November 7, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Thursday, November 7, 2019 | 8:00 am - 12:30 pm
Genetti Hotel & Suite
200 W 4th St
Williamsport, PA 17701Please register with the PA Department of Health prior to the course here: https://www.surveymonkey.com/r/MAT_Summit_Registration
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Johnstown, PA - Wednesday, November 13, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Wednesday, November 13, 2019 | 8:00 am - 12:30 pm
Frank J Pasquerilla Conference Center
301 Napoleon St
Johnstown, PA 15901Please register with the PA Department of Health prior to the course here: https://www.surveymonkey.com/r/MAT_Summit_Registration
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Pittsburgh, PA - Thursday, November 14, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Host: PA Department of Health
Thursday, November 14, 2019 | 8:00 am - 12:30 pm
Westin Pittsburgh
1000 Penn Ave
Pittsburgh, PA 15222Please register with the PA Department of Health prior to the course here: https://www.surveymonkey.com/r/MAT_Summit_Registration
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of live learning followed by 4 hours of online learning. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
- Physicians, Nurse Practitioners, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office based treatment of opioid use disorders.
- Clinicians and health care team members working with physicians who prescribe buprenorphine in office based treatment of opioid use disorders.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Treatment of Opioid Use Disorder: Waiver Qualifying - Pittsburgh, PA - Thursday, October 10, 2019
Contains 6 Component(s), Includes CreditsThe ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine.
Thursday, October 10, 2019 | 12:00 pm - 4:30 pm
Eye & Ear Institute
203 Lothrop Street
Pittsburgh, PA 15213Online Portion Due: Wednesday, October 9, 2019
Overview
Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.
This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course.Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
Module 1
- Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
- Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
- Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
- Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
- Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders
Module 2
- Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
- Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
- Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone
Module 3
- Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
- Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
- Summarize acute and chronic pain management strategies for patients with an opioid use disorder
Overall
Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder
Target Audience
- Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
- Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.
Accreditation & Disclosures
Date of Release: July 2015
Approved Through: December 2019ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit Designation Statement
This program has been reviewed and is approved for a maximum of 8.00 AAPA Category 1 CME credits by the PA Review Panel. Approval is valid for one year from the issue date of 01/01/2018. Participants may submit the post-test at any time during that period. This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.
Disclosures
In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM Treatment of Opioid Use Disorder Course Faculty
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Jill Mattingly, DHSc, MMSc, PA-C None Debra Newman, PA-C, MPAS, MPH None Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, DFASAM
None
ASAM Treatment of Opioid Use Disorder Course Program Planning CommitteeName
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Dan Alford, MD, MPH, DFASAM, Chair
None
Paula J. Lum, MD, MPH, FASAM, Vice Chair
None Edwin Salsitz, MD, DFASAM, Curriculum Director
None
Soraya Azari, MD
None
Jill Mattingly, DHSc, MMSc, PA-C
None
Debra Newman, PA-C, MPAS, MPH
None
Mary McMasters, MD, DFASAM None Yngvild K. Olsen, MD, MPH, DFASAM
None Shawn Ryan, MD, MBA, FASAM None Kristin Smith, DNP, FNP-C, AAHIVS None Tricia E. Wright, MD, MS, FACOG, FASAM None ASAM CME Committee
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Catherine Friedman, MD, FAPA, DFASAM, Chair None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Zwaantje Hamming, FNP-C, CARN-AP None Herbert L. Malinoff, MD, FACP, DFASAM
None
Noel Ilogu, MD, MRCP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants
Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD
None Sandy Metcalfe None ASAM Medical Education Council
Name
Nature of Relevant Financial Relationship
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer CanadaGrant funding
Consulting Fees
Consulting FeesPrincipal
Investigator
Consulting
ConsultingDaniel P. Alford, MD, MPH, DFASAM None Michael Fingerhood, MD, FACP, FASAM None Catherine R. Friedman, MD, FAPA, DFASAM None Adam J. Gordon, MD, MPH, FACP, DFASAM None Miriam S. Komaromy, MD, FACP, DFASAM None Edwin A. Salsitz, MD, DFASAM None Mark P. Schwartz, MD, DFASAM None Mark A. Weiner, MD, FASAM None ASAM Staff and Consultants Penny S. Mills, MBA None Arlene C. Deverman, MA, CAE, CFRE None Marcia Jackson, PhD None Dawn C. Howell None Molly S. Mazuk None Alexandra (Alli) Unger None Jennifer L. Butchart None How to Apply for a Waiver
Physicians
- Fill out the Waiver Notification Form on SAMHSA’s website.
- Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.
SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.
Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.
If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.
Other Approved Prescribers
Apply
NPs and PAs who have completed the 24 hours of required training may seek to obtain a DATA 2000 waiver for up to 30 patients by completing the Waiver Notification Form. Effective February 27, 2017, SAMHSA will only accept electronic submissions of the NOI.
NPs and PAs may send copies of their training certificates to infobuprenorphine@samhsa.hhs.govor fax them to 301.576.5237. These waiver applications are forwarded to the Drug Enforcement Administration (DEA), which will assign the NP or PA a special identification number. DEA regulations require this number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with the NP’s or PA’s regular DEA registration number.
SAMHSA shall review waiver applications within 45 days of receipt. If approved, NPs and PAs will receive a letter via email that confirms their waiver and includes their prescribing identification number.
Qualify
To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete no less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.
Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver. Some states may have overriding state legislation that will prevent NPs from prescribing these medications even if Federal law allows it.
Overview of Legislation
Physicians
The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.
Nurse Practitioners & Physician Assistants
On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.
To qualify, NPs and PAs must:
- Be licensed under state law to prescribe schedule III, IV, or V medications for pain
- Complete not less than 24 hours of appropriate education through a qualified provider
- Through other training or experience, demonstrate the ability to treat and manage OUD
- If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD
HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.
NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:
- 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
- Clinical Tools, Inc
- Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)
The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.
-
Pain Management and Opioids: Balancing Risks and Benefits - Winfield, IL - Saturday, October 12, 2019
Contains 1 Component(s)Earn 2.5 AMA PRA Category 1™ Credit(s) while learning about the latest science, clinical guidelines, and policies around pain and opioids and getting the tools you need to provide evidence-based pain treatment.
Host: Illinois Society of Addiction Medicine
Date:Saturday October 12, 2019 | 8:00 am – 11:00 am
Location: Northwestern Medicine Central DuPage Hospital
Cost: FREE
The misuse of opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:
- From 1999 to 2016 more than 630,000 people died from drug overdoses.
- 115 Americans die every day from an opioid overdose.
The CO*RE/ASAM Pain Management and Opioids: Balancing Risks and Benefits curriculum is newly updated to reflect the latest information in this vital area of healthcare. The thoroughly revised curriculum addresses: the nature and pathophysiology of pain; assessing patients in pain; creating a pain treatment plan; initiating opioid therapy; managing patients on opioid analgesics; educating patients and caregivers; and understanding opioid use disorder. This program meets many states requirements for opioid education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blue Print”), issued by the U.S. Food & Drug Administration in September 2018.
Edwin A. Salsitz
MD, DFASAM
Dr. Edwin A. Salsitz has been an attending physician in the Mount Sinai Beth Israel , Division of Chemical Dependency, New York City, since 1983, and is an Assistant Professor of Psychiatry at the Mount Sinai School of Medicine. He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.
Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease. He has published and lectures frequently on addiction medicine topics.Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings,and is a mentor in the PCSS-MAT mentoring program. He has co-chaired the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art course and is a reviewer for the Journal of Addiction Medicine and Drug and Alcohol Dependence. He is the chair of the ASAM REMS course on safe and effective prescribing of opioids.
Dr. Salsitz was the Co-chair of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. Dr. Salsitz is a member of the medical advisory panel, for the New York State Office of Alcohol and Substance Abuse Services. Dr. Salsitz is the recipient of the 2014 ASAM Annual Award, and the 2018 ASAM Annual Educator of the Year Award.
David Lott
MD
Dr. Lott specializes in Addiction treatment in the Chicago area and is a Clinical Associate Professor of Psychiatry at the University of Illinois College of Medicine in Chicago. He is a Distinguished Fellow of the American Society of Addiction Medicine and the American Psychiatric Association. In addition, he currently serves as a Board member and President-Elect of the Illinois Society of Addiction Medicine.
Dr. Lott received his undergraduate degree from Duke University and completed medical school at Johns Hopkins University. He returned to Chicago for a residency in Psychiatry at The University of Chicago and a fellowship in Addiction Psychiatry at The University of Illinois at Chicago. He is board certified in Psychiatry, Addiction Psychiatry and Addiction Medicine.
Dr. Lott previously led the Addictions Services at Linden Oaks Hospital, part of the Edward-Elmhurst Healthcare system in the western suburbs of Chicago, from 2005 through 2017, where he helped in development of a variety of addiction focused programs. He has published several peer-reviewed articles in the addiction field, remains active in teaching, and provides buprenorphine waiver trainings through ASAM as well as PCSS.
Ernest C. Rose
MD
A graduate of University of Louisville School of Medicine, Dr. Ernest C. Rose completed residency in Anesthesiology, Critical Care, and Pain Management at the University of Iowa. He practiced anesthesia and Pain Management from 1979 through 1996. Dr. Rose transitioned to an exclusive practice of Addiction Medicine in 1997. His practice has covered the field from Levels I through IV.
Dr. Rose’s current practice includes Medical Director of multiple facilities and CEO / Medical Director of Rose Medical Association, Inc . in Peoria IL (methadone maintenance, Level-I, Level-II & DUI) & Rose Medical Association, Inc. in Springfield, IL.
He’s been a Medical Review Officer since 2001, ASAM certified since 2002, and ABAM certified since 2014 and has achieved status as Fellow of the American Society of Addiction Medicine (FASAM). He is a practicing physician and currently serves as President of the Illinois chapter of ASAM (ISAM).
CME Information and Disclosure Listing
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.
The American Society of Addiction Medicine designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the disclosure policies of the American Society of Addiction Medicine (ASAM) and the Accreditation Council for Continuing Medical Education (ACCME), the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the Medical Education Council, the CME Committee, program planning committees and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of the activity. All program planning committee members and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The ASAM CME Committee has reviewed these disclosures and determined that the program planning committee and faculty relationships are not inappropriate in the context of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.
ASAM CME Committee
Name
Commercial Interest
What was received?
For what role?
Catherine R. Friedman, MD, FAPA, DFASAM, Chair
None
R. Jeffrey Goldsmith, MD, DLFAPA, DFASAM
None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
None
Zwaantje Hamming, FNP-C, CARN-AP
None
Noel Ilogu, MD, MRCP, DFASAM
None
Hebert L. Malinoff, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE
None
Marcia Jackson PhD
None
Sandy Metcalfe
None
Program Planning Committee
Name
Commercial Interest
What was received?
For what role?
Herbert Malinoff, MD, FACP, DFASAM
None
Yngvild Olsen, MD, MPH
None
Theodore Parran, MD, FACP
None
Edwin Salsitz, MD, DFASAM
None
R. Corey Waller, MD, MS, FACEP
None
Faculty
Name
Commercial Interest
What was received?
For what role?
Kirk Moberg, MD, FASAM
None
ASAM CME Committee Reviewers
Name
Commercial Interest
What was received?
For what role?
Jacob Bobrowski, MD, FAAFP
None
Anthony H. Dekker, DO, DFASAM
None
ASAM Medical Education Council
Name
Commercial Interest
What was received?
For what role?
Peter Selby, MBBS, CCFP, FCFP, MHSc, DipABAM, DFASAM, Chair
Pfizer
Johnson & Johnson
Pfizer Canada
Grant funding
Consulting Fees
Consulting Fees
Principal Investigator
Consulting
Consulting
Daniel Alford, MD, MPH
None
Michael Fingerhood, MD, FACP, FASAM
None
Catherine R. Friedman, MD, FAPA, DFASAM
None
Adam J. Gordon, MD, MPH, FACP, DFASAM, CMRO
None
Miriam S. Komaromy, MD, FACP, DFASAM
None
Edwin A. Salsitz, MD, DFASAM
None
Mark P. Schwartz, MD, DFASAM
None
Mark A. Weiner, MD, FASAM
None
ASAM Staff and Consultants:
Arlene C. Deverman, MA, CAE, CFRE
None
Marcia Jackson PhD
None
Jennifer L. Butchart
None
Penny S. Mills, MBA
None
Central DuPage Hospital
Inpatient Pavilion Entrance
Bed Tower – Auditorium
25 N. Winfield Rd, Winfield, ILPark in Lots 3, 4, 5 and 6. Allow plenty of time for parking.
-
The ASAM Review Course in Addiction Medicine 2019 (20.5 CME)
Contains 24 Product(s)Earn up to 20.5 CME while preparing for the ABPM Addiction Medicine Exam using this on-demand package of courses, containing the conference recordings, resources, practice questions, and slides from The ASAM Review Course in Addiction Medicine, 2019. The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.
Overview
The ASAM Review Course in Addiction Medicine is widely recognized as the essential primer for physicians and clinicians preparing for a career in addiction medicine, as well as for primary care providers who wish to increase their skills in identifying and managing patients whose medical problems are caused or exacerbated by substance use disorders.
The course offers recorded sessions which are mapped to the addiction medicine exam blueprint of topics for the exam and features an outstanding faculty. ASAM’s Review Course has had a major impact on advancing a common base of scientific knowledge among physicians and other healthcare professionals.
Learning Objectives
Upon completion, participants should be able to:
- Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting
- Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals
- Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders
- Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient
- Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse
Additional Resources
Additional Board Exam Preparation resources and tools are also available.
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The ASAM CME Committee and Reviewers Disclosure Listing
First Name Commercial Interests Compensation Received For what Role? Timothy Brennan MD, MPH, FASAM None Jeffrey DeVido MD Altria/Philip Morris Stock Inheritance Paul Earley MD, DFASAM Alkermes, Inc; DynamiCare Health, Inc honoraria; Salary Speaker; VP of Medical Affairs James Finch MD, DFASAM None Marc Fishman MD, DFASAM US World Meds; Alkermes consulting fee, travel; honoraria Consultant; Advisory board David Galbis-Reig MD, DFASAM Ascension Wisconsin All Saints; Abbvie; Hospira; RespireRX Pharmaceuticals; Abbott Pharmaceuticals; Pfizer Bond Stock& Bond in Retirement IRA; Stock Options; Ownership Interests Owner; Advisory board; PI; Consultant Adam Gordon, MD, MPH None Leslie Hayes, MD None Abigail Herron DO, DFASAM None Petros Levounis MD, MA, FASAM None Carla Marienfeld MD None Ricardo Restrepo MD, MPH, FASAM None Richard Ries MD, DFASAM None Edwin Salsitz MD, DFASAM None Sharon Stancliff MD, FASAM None Timothy Wiegand MD, FACMT, FAACT None Erin Zerbo, MD None ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 20.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 20.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 20.5 AMA PRA Category 1 Credit(s)™ for completing this course.
Upon completion, participants should be able to:
- Demonstrate practical knowledge on the neurobiology of addiction and articulate its activity in terms useful in a clinical setting.
- Describe the effects of alcohol, tobacco and other drugs in both tolerant and non-tolerant individuals.
- Describe the process for diagnosing addiction and differentiating the symptoms of addiction from those of other medical or psychiatric disorders.
- Explain the various pharmacologic and psychosocial treatments for addictive disorders and describe the factors that should be considered in selecting a treatment modality to match the needs of a specific patient.
- Describe the precipitants of relapse and current evidence-based practices to prevent and manage relapse.
The ASAM Review Course in Addiction Medicine provides an up-to-date review of the core content of addiction medicine for:
- Physicians preparing for the ABPM Board Certification/Recertification Examination in addiction medicine
- Addiction specialists seeking a "refresher" course that incorporates recent developments in addiction science and practice
- Non-specialist physicians and other healthcare professionals needing the knowledge to identify and manage problems related to substance use disorders for their patients
-
ASAM Criteria Course - Salisbury, MD - Monday, December 2, 2019
Contains 4 Component(s), Includes CreditsThe ASAM Criteria Course is a practical workshop designed to help counselors, social workers, administrators, and other clinical staff develop patient-centered service plans and make objective decisions about patient admission, continuing care, and transfer/discharge for individuals with addictive, substance-related, and co-occurring conditions.
Monday, December 2, 2019
8:00 am - 4:30 pm
Hampton Inn Salisbury
121 E. Naylor Mill Road
Salisbury, MD 21801
Alvin Snyder RoomOverview
The ASAM Criteria Course will comprise of a comprehensive suite of competency-based learning activities that meets the learning needs of the multiple audiences making use of the Criteria and results in the appropriate use of the Criteria in practice. The ASAM Criteria Course can also serve as a bridge to the implementation of a provider credentialing program. Providers who have completed ASAM approved training on The ASAM Criteria can gain the initial skill set to deliver care in compliance with The ASAM Criteria.
Getting Started
To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions." If you have any questions, please contact education@ASAM.org.
Learning Objectives
- Describe the underlying principles and concepts of the ASAM Criteria.
- Identify the six dimensions of the ASAM Criteria’s multidimensional patient assessment.
- Determine treatment priorities based on risk assessment to guide treatment and service planning.
- Determine an appropriate level of care and treatment priorities based on risk assessment.
- Implement the ASAM Criteria, in the context of system challenges, for patients with addiction to ensure appropriate level of care and treatment outcomes.
Anika Alvanzo
MD, MS, FASAM, FACP
Anika Alvanzo, MD, MS is an Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine where she is also the Medical Director of the Johns Hopkins Hospital Substance Use Disorders Consultation Service (SUDS). Dr. Alvanzo is a graduate of the George Washington University School of Medicine and Health Sciences and holds a master's degree in biostatistics from Virginia Commonwealth University. She is board certified in both Internal Medicine and Addiction Medicine. As the Director of the SUDS, Dr. Alvanzo oversees a multidisciplinary consultation service that performs brief behavioral interventions and counseling for hospitalized patients, facilitates linkage to hospital and community-based alcohol and drug treatment programs, provides guidance on the clinical management of substance withdrawal syndromes, and educates patients, families, healthcare professionals and the community to prevent, identify, and treat persons living with addiction. Dr. Alvanzo is also the Director of the Substance Use Disorders Rotation for the Johns Hopkins Medicine-Pediatrics Urban Health and Urban Health Primary Care Residency track programs. Her research interests include gender and race/ethnicity differences in the risk for substance use disorders, integration of technology for screening, brief intervention and referral to treatment in diverse settings and the association between psychological trauma, traumatic stress, and substance use. In particular, she is interested in the mechanisms by which histories of physical and/or sexual violence confer increased risk for substance use disorders and in the development of interventions for co-occurring traumatic stress and substance misuse in women.
Christine R. Mulford
RN, MSN, FNP-BC
Christine brings her more than 15 years of clinical and leadership experience as a Nurse Practitioner to the practice of addiction medicine. She is passionate about individualized patient care as well as community education to end the stigma of substance use and mental health issues.
Together with her physician partner, she started the first Emergency Room based
withdrawal management service in the greater Phoenix area. Additionally, she maintains a private addiction medicine practice in Scottsdale, Arizona. Christine received her Master’s Degree in Nursing from Vanderbilt University where she was the 1998 Julia Hereford Merit Scholar. She resides in Phoenix, Arizona with her 2 sometimes well-behaved dogs. She enjoys live music, sports, and trying new hot sauces.- Registration Closed. Maximum Number of Registrants reached.
- More Information